Northstar-3: Interim Results from a Phase 3 Study Evaluating Lentiglobin Gene Therapy in Patients with Transfusion-Dependent ß-Thalassemia and Either a ß0 or IVS-I-110 Mutation at Both Alleles of the HBB Gene.

Blood

Ashutosh Lal, Franco Locatelli, Janet L. Kwiatkowski, Andreas E. Kulozik, Evangelia Yannaki, John B. Porter, Isabelle Thuret, Martin G. Sauer, Heidi Elliot, Ying Chen, Richard A. Colvin, Alexis A. Thompson. Northstar-3: Interim Results from a Phase 3 Study Evaluating Lentiglobin Gene Therapy in Patients with Transfusion-Dependent ß-Thalassemia and Either a ß0 or IVS-I-110 Mutation at Both Alleles of the HBB Gene. Blood. 2019 Nov 13; 134(Supplement_1):815-815.

2019

https://researcherprofiles.org/profile/151837461

Northern California Comprehensive Thalassemia Center

Search form

You are here

Northstar-3: Interim Results from a Phase 3 Study Evaluating Lentiglobin Gene Therapy in Patients with Transfusion-Dependent ß-Thalassemia and Either a ß0 or IVS-I-110 Mutation at Both Alleles of the HBB Gene.